Prof. Dr. Thomas Lehrnbecher | Medicine | Goethe Universität Frankfurt | Germany
Dr. Thomas Lehrnbecher is a distinguished pediatric oncologist and hematologist, serving as Head of the Division of Pediatric Hematology and Oncology at Johann Wolfgang Goethe University, Frankfurt. With decades of experience, his clinical and research expertise lies in infections in immunocompromised pediatric patients, supportive care, and innovative therapeutic strategies for childhood cancers. His career spans leading roles in Germany and international collaborations at the National Cancer Institute, USA, where he trained as a post-doctoral fellow. A prolific researcher, he has published extensively in high-impact journals, shaping global practices in infection management and antifungal prophylaxis in children with cancer. Dr. Lehrnbecher has also contributed significantly to medical societies, committees, and working groups, reflecting his leadership in advancing pediatric oncology. Recognized with prestigious awards, he continues to drive progress in medicine through innovative research, clinical care, and mentorship, making him an influential figure in pediatric hematology and oncology worldwide.
Author profile
Orcid
Education
Dr. Lehrnbecher’s medical training reflects a strong foundation in pediatrics and subspecialization in oncology and infectious diseases. He earned his Board Exam in General Pediatrics in 1996, establishing his clinical foundation. His academic excellence and leadership were recognized in 2005, when he was awarded a Professorship at Johann Wolfgang Goethe University, Frankfurt, one of Germany’s leading medical institutions. That same year, he also earned a Diploma in Pediatric Infectious Diseases from the German Society for Pediatric Infectious Diseases, strengthening his expertise in managing complex infections. In 2007, he completed his Board Exam in Pediatric Hematology and Oncology, formally certifying his specialization in childhood cancers and blood disorders. Combined with his post-doctoral fellowship at the National Cancer Institute (NIH, USA), his education and training provided him with exceptional clinical and research competencies, which now serve as the foundation of his international reputation in pediatric oncology and infection medicine.
Experience
Dr. Lehrnbecher has cultivated an impressive career spanning over two decades in pediatric hematology and oncology. Since 2001, he has served as a Senior Consultant at Johann Wolfgang Goethe University, Frankfurt, providing expertise in pediatric cancer care and mentoring young clinicians. In 2018, he advanced to Head of the Division of Pediatric Hematology and Oncology, where he oversees patient care, clinical programs, and research initiatives. Earlier in his career, he worked as a Consultant at the Children’s Hospital, University of Würzburg (1999–2000), where he gained valuable clinical insights. A pivotal moment came during his post-doctoral fellowship at the National Cancer Institute, NIH, USA (1996–1999), under Dr. Stephen Chanock, where he developed a strong research focus on infections in immunocompromised children. His leadership in both clinical and research settings reflects his dedication to integrating science with practice, driving advancements in pediatric oncology, supportive care, and infection management worldwide.
Awards and Honors
Dr. Lehrnbecher’s contributions to pediatric oncology and infectious diseases have earned him numerous prestigious awards. In 2024, he received the Best Publication Award from the German Society of Mycology (DMykG), recognizing his impactful research. He previously won the Kind Philipp Award from the German Society of Pediatric Oncology and Hematology (GPOH) and the Poster Award from the International Society of Pediatric Oncology (SIOP). His groundbreaking work in mycology earned him the Outstanding Research in Mycology Award, while his contributions to histiocytic disorders were honored with the Nesbit Award from the Histiocyte Society. Earlier in his career, he was recognized with the Outstanding Research Award in Novel Therapeutic Strategies by the Children’s Cancer Foundation Mainz and the Educational Grant from the German Foundation of Cancer Aid. Collectively, these awards highlight his sustained excellence in clinical care, medical research, and innovation.
Research Focus
Dr. Lehrnbecher’s research is centered on improving the management of infections in immunocompromised pediatric patients, particularly those undergoing cancer treatment or hematopoietic stem cell transplantation. He has extensively studied antifungal prophylaxis, bacterial infections, and novel diagnostic markers for invasive fungal disease in children. His investigations aim to refine supportive care strategies, reduce infection-related mortality, and improve the quality of life for pediatric cancer patients. A particular focus of his research has been the efficacy of antifungal and antibiotic therapies, as well as the development of evidence-based guidelines for infection management. Beyond infectious diseases, his work also contributes to optimizing cancer treatment protocols, including long-term maintenance therapies for pediatric sarcomas. Through clinical trials, prospective studies, and international collaborations, Dr. Lehrnbecher has made significant advances in pediatric oncology. His contributions are widely recognized for bridging research and practice, helping set global standards for supportive care in children with cancer.
Publications
-
Assessing the Theoretical Efficacy of Combination Therapy Against Gram-Negative Infections in Neutropenic Pediatric Cancer Patients.
-
Mold-Active Antifungal Prophylaxis in Pediatric Patients with Cancer or Undergoing Hematopoietic Cell Transplantation.
-
Pediatric Patients with Stage IV Rhabdomyosarcoma Benefit from Long-Term Maintenance Therapy: CWS Trials Results.
-
Serum Beta-D-Glucan in the Diagnosis of Invasive Fungal Disease in Children: A Critical Analysis.
-
Cerebrospinal Fluid System Infection in Children with Cancer: A 14-Year Retrospective Analysis.
-
Infections during Non-Neutropenic Episodes in Pediatric Cancer Patients: A Prospective European Study.
Conclusion
Dr. Thomas Lehrnbecher is an internationally recognized leader in pediatric oncology and infectious diseases. His pioneering research, clinical leadership, and commitment to advancing supportive care in childhood cancer treatment have transformed patient outcomes worldwide. His achievements and continued impact make him a highly deserving candidate for the Medicine Award, symbolizing excellence in medical research and clinical innovation.